Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock is trading at $17.53, up 5.29%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TEVA shares have gain 5.03% over the last week, with a monthly amount drifted -4.99%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] stock has seen the most recent analyst activity on July 10, 2024, when Argus upgraded its rating to a Buy but kept the price target unchanged to $20 for it. Previously, JP Morgan upgraded its rating to Neutral on March 08, 2024, and kept the price target unchanged to $14. On February 12, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $19 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $14 on January 23, 2024. Piper Sandler upgraded its rating to a Neutral and raised its price target to $12 on January 03, 2024. HSBC Securities started tracking with a Buy rating for this stock on December 18, 2023, and assigned it a price target of $13. In a note dated November 27, 2023, UBS upgraded an Buy rating on this stock and boosted its target price from $11 to $13.
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock has fluctuated between $9.35 and $19.31 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] shares were valued at $17.53 at the most recent close of the market. An investor can expect a potential return of 14.09% based on the average TEVA price forecast.
Analyzing the TEVA fundamentals
Teva- Pharmaceutical Industries Ltd. ADR [NYSE:TEVA] reported sales of 16.81B for the trailing twelve months, which represents a growth of 13.40%. Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at -0.03%, and Net Profit Margin reading is -0.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.15 and Total Capital is 0.08. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.00 points at the first support level, and at 16.46 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.93, and for the 2nd resistance point, it is at 18.32.
Ratios To Look Out For
For context, Teva- Pharmaceutical Industries Ltd. ADR’s Current Ratio is 0.89. In addition, the Quick Ratio stands at 0.61 and the Cash Ratio stands at 0.24. Considering the valuation of this stock, the price to sales ratio is 1.18, the price to book ratio is 3.28.
Transactions by insiders
Recent insider trading involved Fox Christine, EVP, Head of U.S. Commercial, that happened on Nov 20 ’24 when 19388.0 shares were sold. Officer, Fox Christine completed a deal on Nov 20 ’24 to buy 19388.0 shares. Meanwhile, Exec. VP, European Commercial Daniell Richard sold 98943.0 shares on Aug 12 ’24.
